38 Small Cap Stocks Just Made New 52-Week Highs
A concentrated list of new market leaders emerges from a quiet tape.
While the S&P 500 returned 3.3% over the last month, one name on today’s 52-week-high list, Crinetics Pharmaceuticals (CRNX), gained 143.8%. As of Monday, July 13, it is one of 38 Small Cap stocks from the Russell 3000 at its strongest price of the past year.
The central question is what to make of the list’s heavy concentration in financials, with Regional Banks and Life & Health Insurance each contributing 4 names. Below are the stocks hitting new highs.
The Complete 52-Week-High List
- Has Nike Stock’s Direct-to-Consumer Engine Stalled For Good?
- What BKR’s Management Still Has To Prove
- SpaceX Stock Down 30%. Can Starship Flight 13 Turn It Around?
- Down 49%, Is RKLB Stock Grounded In Reality Or Ready For Liftoff?
- How Deep Can Oracle Stock Fall?
- The Power Plant Signal Hiding Inside Caterpillar Stock
The table below shows the 10 largest of the 38 names, sorted by market capitalization, with returns over four windows:
| Tickers | Market Cap |
1D % Chg |
1W % Chg |
1M % Chg |
1Y % Chg |
|---|---|---|---|---|---|
| CFR | $10.0 Bil | 0.7% | 1.0% | 9.3% | 18.3% |
| PRI | $9.8 Bil | 1.9% | 3.7% | 12.2% | 18.0% |
| NUVL | $9.8 Bil | 0.0% | 0.2% | 0.5% | 51.0% |
| APGE | $9.3 Bil | 0.1% | 0.2% | 61.8% | 247.0% |
| VOYA | $9.2 Bil | 1.4% | 2.8% | 11.0% | 38.6% |
| CRNX | $8.7 Bil | 0.1% | 99.1% | 143.8% | 161.6% |
| FR | $8.6 Bil | 0.1% | 3.3% | 5.1% | 37.1% |
| AXS | $8.5 Bil | 1.3% | 1.3% | 15.1% | 20.1% |
| JXN | $8.4 Bil | 3.5% | 10.5% | 14.2% | 42.1% |
| EAT | $8.2 Bil | 2.2% | 7.4% | 28.4% | 13.5% |
Financials on the list show business growth behind their price strength.
Cullen/Frost Bankers (CFR), the largest company on the list with a market value of about $10.0 billion, has gained 9.3% over the last month. That new high is accompanied by revenue that grew 8.0% over the last twelve months, and the stock trades at 14.9 times trailing earnings.
Primerica (PRI), with a market value of about $9.8 billion, shows a similar pattern. Its 12.2% gain over the last month is supported by revenue growth of 6.4% over the last twelve months, and it trades at 12.7 times trailing earnings.
A new high is a starting point for research, not a conclusion.
A stock at its strongest price of the last year is a sign of market recognition. Strength can persist. But a price is simply what the market is willing to pay today, not a final verdict on a company’s value.
The disciplined next step is to investigate whether the underlying business fundamentals justify the new price level. The list is a screen, and the real work begins after reading it.
A new high tells you what the market already believes. The harder question is which of these runs management itself is underwriting. Our Guidance Momentum screen tracks exactly that: stocks where the company raised its own forward numbers.
New Highs Feel Great. Concentration Decides How They End
If a stock you own is on this list, the gain is real – and so is the way winners quietly grow into most of a portfolio right before their worst stretch. Trimming a big winner the usual way means handing a chunk of those gains to the IRS. There is a way to lock in the gains and diversify without the tax hit.